ENTREMED, INC. SUMMARY OF OPERATING RESULTS Three Months Ended March 31, | |||
2011 | 2010 | ||
Total revenues | $0 | $0 | |
Research and development | $1,398,274 | $843,953 | |
General and administrative | $1,253,105 | $1,051,225 | |
Net Loss | $(2,596,379) | $(2,126,144) | |
Net loss per share attributable to common shareholders (basic and diluted) | |||
$(0.25) | $(0.28) | ||
Weighted average number of shares outstanding (basic and diluted) | |||
11,444,711 | 8,540,812 | ||
Cash and Short-term Investments | $4,828,893 | $9,691,834 | |
